NOOTROPIL Piracetam 800mg Film-Coated Tablet 1's

Symptoms: No additional adverse events specifically related to overdose have been reported with piracetam (Nootropil). The highest reported overdose with piracetam (Nootropil) was oral intake of 75 g wherein bloody diarrhoea with abdominal pain, was most probably related to the extreme high dose of sorbitol contained in the used formulation.
Treatment: There is no specific antidote for overdose with piracetam (Nootropil). Treatment for an overdose should be symptomatic and may include haemodialysis. The extraction efficiency of the dialyser is 50 to 60% for piracetam (Nootropil). Further management should be as clinically indicated or as recommended by the national poisons centre, where available.

 

 

Fertility: There are no relevant data available.
Pregnancy: Piracetam (Nootropil) should not be used during pregnancy unless clearly necessary, when benefit exceeds the risks and the clinical condition of the pregnant mother requires treatment with piracetam (Nootropil). Piracetam (Nootropil) crosses the placental barrier. Drug levels in the newborn are approximately 70% to 90% of maternal levels. There are no adequate data from the use of piracetam (Nootropil) in pregnant women. Animal studies do not indicate direct or indirect harmful effects with respect to pregnancy, embryonal/foetal development, parturition or post-natal development.
Lactation: Piracetam (Nootropil) should not be used during breastfeeding or breastfeeding should be discontinued, while receiving treatment with piracetam (Nootropil). Piracetam (Nootropil) is excreted in human breast milk. A decision must be made whether to discontinue breast-feeding or to discontinue piracetam (Nootropil) therapy taking into account the benefit of breastfeeding for the child and the benefit of therapy for the woman.

 

Incompatibilities: None known.

 

Piracetam (Nootropil) 800 mg and 1200 mg film coated tablet: Store at temperatures not exceeding 30°C.

 

Pharmacology: Pharmacodynamics: Mechanism of Action: Available data suggest that piracetam basic mechanism of action is neither cell nor organ specific. Piracetam binds physically in a dose-dependent manner to the polar head of phospholipids membrane models, inducing the restoration of the membrane lamellar structure characterized by the formation of mobile drug phospholipid complexes. This probably accounts for an improved membrane stability, allowing the membrane and transmembrane proteins to maintain or recover the 3-dimensional structure or folding essential to exert their function. Piracetam has neuronal and vascular effects.
Neuronal Effect: At the neuronal level, piracetam exerts its membrane activity in various ways. In animals, piracetam enhances a variety of types of neurotransmission, primarily through postsynaptic modulation of receptor density and activity. In both animals and man, the functions involved in cognitive processes eg, learning, memory, attention and consciousness were enhanced in the normal subject as well as in deficiency states without the development of sedative or psychostimulant effects. Piracetam protects and restores cognitive abilities in animals and man after various cerebral insults such as hypoxia, intoxications and electroconvulsive therapy. It protects against hypoxia-induced changes in brain function and performance as assessed by electroencephalograph (EEG) and psychometric evaluations.
Vascular Effects: Piracetam applies its haemorrhagic effect to thrombocytes, erythrocytes and the walls of the blood vessels by increasing the deformability of erythrocytes, reducing the aggregability of throbocytes, reduces the adhesion of erythrocytes to the walls of vessels and reduces capillary vasospasm.
Effects on the Red Blood Cells: In patients with sickle cell anemia, piracetam improves the deformability of the erythrocyte membrane, decreases blood viscosity and prevents rouleaux formation.
Effects on Platelets: In open studies in healthy volunteers and in patients with Raynaud's phenomenon, increasing doses of piracetam up to 12 g was associated with a dose-dependent reduction in platelet functions compared with pre-treatment values (tests of aggregation induced by ADP, collagen, epinephrine and βTG release), without significant change in platelet count. In these studies, piracetam prolonged bleeding time.
Effects on Blood Vessels: In animal studies, piracetam inhibited vasospasm and counteracted the effects of various spasmogenic agents. It lacked any vasodilatory action and did not induce "steal" phenomenon, nor low or no reflow, nor hypotensive effects. In healthy volunteers, piracetam reduced the adhesion of RBCs to vascular endothelium and possessed also a direct stimulant effect on prostacycline synthesis in healthy endothelium.
Effects on Coagulation Factors: In healthy volunteers, compared with pre-treatment values, piracetam up to 9.6 g reduced plasma levels of fibrinogen and von Willebrand's factors (VIII: C; VIII R: AG; VIII R: vW) by 30% to 40% and increased bleeding time. In patients with both primary and secondary Raynaud's phenomenon, compared with pretreatment values, piracetam 8 g/d during 6 months reduced plasma levels of fibrinogen and von Willebrand's factors [VIII:C; VIII R: AG; VIII R: vW (RCF)] by 30% to 40%, reduced plasma viscosity and increased bleeding time.
Pharmacokinetics: The pharmacokinetic profile of piracetam is linear and time-dependent with low intersubject variability over a large range of doses. This is consistent with the high permeability, high solubility and minimal metabolism of piracetam. Plasma half-life of piracetam is 5 hours. It is similar in adult volunteers and in patients. It is increased in the elderly (primarily due to impaired renal clearance) and in subjects with renal impairment. Steady-state plasma concentrations are achieved within 3 days of dosing.
Absorption: Piracetam is rapidly and extensively absorbed following oral administration. In fasted subjects, the peak plasma concentrations are achieved 1 hour after dosing. The absolute bioavailability of piracetam oral formulations is close to 100%. Food does not affect the extent of absorption of piracetam but it decreases C_max by 17% and increases T_max from 1 to 1.5 hours. Peak concentrations are typically 84 μg/mL and 115 μg/mL following a single oral dose of 3.2 g and repeat dose of 3.2 g twice daily, respectively.
Distribution: Piracetam is not bound to plasma proteins and its volume of distribution is approximately 0.6 L/kg. Piracetam crosses the blood brain barrier as it has been measured in cerebrospinal fluid following intravenous administration. In cerebrospinal fluid, the T_max was achieved about 5 hours post-dose and the half-life was about 8.5 hours. In animals, piracetam's highest concentrations in the brain were in the cerebral cortex (frontal, parietal and occipital lobes), in the cerebellar cortex and basal ganglia. Piracetam diffuses to all tissues except adipose tissues, crosses placental barrier and penetrates the membranes of isolated red blood cells.
Metabolism: Piracetam is not known to be metabolized in the human body. This lack of metabolism is supported by the lengthy plasma half-life in anuric patients and the high recovery of parent compound in urine.
Elimination: The plasma half-life of piracetam in adults is about 5 hours following either intravenous or oral administration. The apparent total body clearance is 80-90 mL/min. The major route of excretion is via urine, accounting for 80 to 100% of the dose. Piracetam is excreted by glomerular filtration.
Linearity: The pharmacokinetics of piracetam are linear over the dose range of 0.8 to 12 g. Pharmacokinetic variables like half-life and clearance are not changed with respect to the dose and the duration of treatment.
Special Patient Populations: Children: No formal pharmacokinetic study has been conducted in children.
Elderly: In the elderly, the half-life of piracetam is increased and the increased is related to the decrease in renal function in this population (see Dosage & Administration).
Renal Impairment: Piracetam clearance is correlated to CrCl. It is therefore recommended to adjust the daily dose of piracetam based on creatinine clearance in patients with renal impairment (see Dosage & Administration). In anuric end-stage renal disease subjects, the half-life of piracetam is increased up to 59 hours. The fractional removal of piracetam was 50 to 60% during a typical 4-hour dialysis session.
Hepatic Impairment: The influence of hepatic impairment on the pharmacokinetics of piracetam has not been evaluated. Because 80 to 100% of the dose is excreted in the urine as unchanged drug, hepatic impairment solely would not be expected to have a significant effect on piracetam elimination.
Other patient characteristics: Gender: In a bioequivalence study comparing formulations at a dose of 2.4 g, C_max and AUC were approximately 30% higher in women (N=6) compared to men (N=6). However, clearances adjusted for body weight were comparable.
Race: Formal pharmacokinetic studies of the effects of race have not been conducted. Cross study comparisons involving Caucasians and Asians, however, show that pharmacokinetics of piracetam were comparable between the two races. Because piracetam is primarily renally excreted and there are no important racial differences in creatinine clearance, pharmacokinetic differences due to race are not expected.
Toxicology: Non-Clinical Information: The preclinical data indicate that piracetam has a low toxicity potential. Single dose studies showed no irreversible toxicity after oral doses of 10 g/kg in mice, rats and dogs. No target organ for toxicity was observed in repeated dose, chronic toxicity studies in mice (up to 4.8 g/kg/day) and in rats (up to 2.4 g/kg/day). Mild gastrointestinal effects (emesis, change in stool consistency, increased water consumption) were observed in dogs when piracetam was administered orally for one year at a dose increasing from 1 to 10 g/kg/day. Similarly, IV administration of up to 1 g/kg/day for 4-5 weeks in rats and dogs did not produce toxicity. In vitro and in vivo studies have shown no potential for genotoxicity and carcinogenicity.